ROLE OVERVIEW
We are currently looking for a Machine Learning Scientist to join a leading pharmaceutical company based in the Cambridge area. As the Machine Learning Scientist, you will be responsible for driving the development of innovative machine learning methods for structure-based drug discovery.
KEY DUTIES AND RESPONSIBILITIES:
Your duties as the Machine Learning Scientist will be varied however the key duties and responsibilities are as follows:
A fantastic opportunity has arisen for a Principal Scientist – Discovery & Translational Biology to join a high-potential drug-development start-up, who are focussed on developing new oncology therapeutics that significantly improve overall survival for patients with a high unmet need. Our client is at the cutting edge of oncology therapeutics, triggering a new wave in target discovery by using proprietary algorithms to identify novel protein fingerprints from a comprehensive membrane protein database.
There can often be a big distinction between how some people visibly and quickly rise in a workplace whilst others stay out of sight. The easy assumption to make is that they are not ready or capable. But when leadership potential goes unrecognised, it’s not always about lack of talent but can be a quiet accumulation of bias, assumptions, and outdated norms.
Sandwich, UK - 10 September 2025: Discovery Park, Kent’s thriving life science and innovation community, today welcomed eight promising cardiovascular and cardiometabolic health startups to its campus. The cohort are embarking on the ‘Discovery Spark’ business growth programme, championing and supporting early stage business working on innovations in heart health.
LONDON, September 10, 2025 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for the Cell and Gene Therapy Catapult (CGT Catapult) and is pleased to announce the placement of Dr. Ed Samuel as Chief Operations Officer (COO).
Recently, Medicilon officially obtained the Good Laboratory Practice (GLP) certification certificate issued by Mexico, a member country of the OECD. In addition, we successfully passed GLP on-site inspections conducted by Hungary.
Following recent FDA and PMDA GLP audits, this achievement reaffirms that Medicilon’s preclinical research quality continues to meet the highest international standards.
Creative Biolabs delivers customized preparation solutions to solve the tough challenges facing membrane protein discovery, ensuring to yield proteins that remain functional and ready for downstream applications.
London, UK, 8 September 2025 – Myricx Bio (‘Myricx’), a UK-based biotech company focusing on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), is pleased to announce the appointment of Jonathon Marks-Bluth, Ph.D., to its leadership team in the newly created position of VP, Business Development.
• Oversubscribed £50m Series B led by SV Health Investors’ Dementia Discovery Fund, alongside other new investors British Business Bank, M Ventures, Novartis Venture Fund and Criteria Bio Ventures, together with existing investors Omega Funds and Brandon Capital
• The financing will enable NRG Therapeutics to deliver clinical proof of concept in ALS/MND with NRG5051, a first-in-class, oral inhibitor of the mitochondrial permeability transition pore (mPTP)
Pioneer Group, a specialist in life science infrastructure and venture building, has once again teamed up with global biopharmaceutical company AbbVie to launch a Golden Ticket programme designed to accelerate companies developing novel, transformational therapies and innovations for immunology, oncology, neurology, eye care, aesthetics, or other specialities including obesity, GI and hepatology.